Cargando…

The use of tafasitamab in diffuse large B-cell lymphoma

Patients who relapse or are refractory after first-line therapy for diffuse large B-cell lymphoma (DLBCL) frequently have poor prognoses, especially when they are not candidates for autologous stem cell transplant (ASCT). Tafasitamab is a humanized monoclonal anti-CD19 antibody that has recently bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Düll, Johannes, Topp, Max, Salles, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264734/ https://www.ncbi.nlm.nih.gov/pubmed/34285786 http://dx.doi.org/10.1177/20406207211027458

Ejemplares similares

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma
por: Roster, Katie, et al.
Publicado: (2023)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

P1227: COMPREHENSIVE MOLECULAR SUBTYPING OF DIFFUSE LARGE B-CELL LYMPHOMA CELL LINES AND ASSOCIATION WITH TAFASITAMAB ACTIVITY
por: Arora, Arshi, et al.
Publicado: (2023)

PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Duell, Johannes, et al.
Publicado: (2023)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
por: Duell, Johannes, et al.
Publicado: (2021)

Diffuse large B-cell lymphoma: new targets and novel therapies
por: Cheson, Bruce D., et al.
Publicado: (2021)

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
por: Patra-Kneuer, Maria, et al.
Publicado: (2023)

PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Nowakowski, G. S., et al.
Publicado: (2022)

Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper
por: Bailly, Sarah, et al.
Publicado: (2022)

Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison
por: Cordoba, Raul, et al.
Publicado: (2022)

PB2112: MINDWAY: A PHASE IB/II DOSE OPTIMIZATION STUDY TO ASSESS SAFETY AND PHARMACOKINETICS OF TAFASITAMAB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Greil, R., et al.
Publicado: (2022)

Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy
por: Her, Jung Hyun, et al.
Publicado: (2022)

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2023)

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
por: Belada, D., et al.
Publicado: (2022)

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2023)

Treatment of Diffuse Large B Cell Lymphoma
por: Kwak, Jae-Yong
Publicado: (2012)

Inflammatory Cells in Diffuse Large B Cell Lymphoma
por: Tamma, Roberto, et al.
Publicado: (2020)

Genomics of diffuse large B cell lymphoma
por: Koh, Youngil
Publicado: (2021)

Lenalidomide in Diffuse Large B-Cell Lymphomas
por: Chiappella, Annalisa, et al.
Publicado: (2012)

Lenalidomide in Diffuse Large B-Cell Lymphoma
por: Thieblemont, Catherine, et al.
Publicado: (2012)

Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm
por: Liu, Ying, et al.
Publicado: (2022)

Diffuse Large B-Cell Lymphoma in the HIV Setting
por: Huguet, Maria, et al.
Publicado: (2023)

Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles
por: Dubois, Sydney, et al.
Publicado: (2019)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
por: Vitolo, U., et al.
Publicado: (2022)

Germline mutations predisposing to diffuse large B-cell lymphoma
por: Leeksma, O C, et al.
Publicado: (2017)

New Insights into Diffuse Large B-Cell Lymphoma Pathobiology
por: Solimando, Antonio Giovanni, et al.
Publicado: (2020)

Non-Coding RNAs in Diffuse Large B-Cell Lymphoma
por: Shi, Yan, et al.
Publicado: (2020)

New agents and regimens for diffuse large B cell lymphoma
por: Wang, Liang, et al.
Publicado: (2020)

How I treat diffuse large B-cell lymphoma
por: Melchardt, T., et al.
Publicado: (2023)

The Metabolism and Immune Environment in Diffuse Large B-Cell Lymphoma
por: Wu, Jianbo, et al.
Publicado: (2023)

T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update
por: Balendran, Shalini, et al.
Publicado: (2023)

Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1
por: Salles, Gilles, et al.
Publicado: (2021)

Immune targeted therapy for diffuse large B cell lymphoma
por: Zheng, Yaxin, et al.
Publicado: (2021)

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma
por: Gouveia, Gisele Rodrigues, et al.
Publicado: (2012)

Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n7jpbqut0ilb9sp21e8v4c6cgt